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Abstract: Cyanobacteria are recognized producers of a wide array of toxic or otherwise
bioactive secondary metabolites. The present study utilized the zebrafish (Danio rerio)
embryo as an aquatic animal model of vertebrate development to identify, purify and
characterize lipophilic inhibitors of development (i.e., developmental toxins) from an isolate
of the freshwater cyanobacterial species, Aphanizomenon ovalisporum. Bioassay-guided
fractionation led to the purification, and subsequent chemical characterization, of an
apparent homologous series of isotactic polymethoxy-1-alkenes (1–6), including three
congeners (4–6) previously identified from the strain, and two variants previously
identified from other species (2 and 3), as well as one apparently novel member of the
series (1). Five of the PMAs in the series (1–5) were purified in sufficient quantity for
comparative toxicological characterization, and toxicity in the zebrafish embryo model was
found to generally correlate with relative chain length and/or methoxylation. Moreover,
exposure of embryos to a combination of variants indicates an apparent synergistic
interaction between the congeners. Although PMAs have been identified previously in
cyanobacteria, this is the first report of their apparent toxicity. These results, along with the
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previously reported presence of the PMAs from several cyanobacterial species, suggest a
possibly widespread distribution of the PMAs as toxic secondary metabolites and warrants
further chemical and toxicological investigation.
Keywords: cyanobacteria; Aphanizomenon ovalisporum; toxins; zebrafish (Danio rerio)
embryo; polymethoxy-1-alkenes; vertebrate development; harmful algal blooms (HABs)

1. Introduction
Cyanobacteria (―blue-green algae‖) are known to produce a diverse repertoire of biologically active
secondary metabolites [1]. When associated with so-called ―harmful algal blooms‖, particularly in
freshwater systems, a number of these metabolites have been associated—as ―toxins‖, or commonly
―cyanotoxins‖—with human and animal health concerns [1–3]. The most widely recognized of the
cyanobacterial toxins currently include hepatotoxic peptides (i.e., microcystins, nodularins) alkaloids
(i.e., cylindrospermopsin), and neurotoxic alkaloids, including both representatives of the
―saxitoxin family‖ of voltage-gated sodium channel inhibitors, and inhibitors of acetylcholine
neurotransmitter pathways (i.e., anatoxin-a and anatoxin-a(s)). More recently, the amino acid analog,
β-methylamino-L-alanine (BMAA), has been additionally linked to neurodegenerative diseases [4],
although this remains to some extent controversial [5]. As health concerns have largely been
associated with exposure to drinking water contaminated with these toxins (except BMAA), it is
notable, although perhaps not surprising, that all of these recognized toxins are generally polar and
water-soluble metabolites.
In several previous studies [6–8], we have utilized the zebrafish (Danio rerio) embryo, as a model
of vertebrate development, and specifically a toxicological (i.e., bioassay) system, to investigate
―developmental toxicity‖ (i.e., inhibition or impairment of developmental pathways) of cyanobacterial
secondary metabolites. The zebrafish embryo has become an increasingly important vertebrate model
owing to a number of practical advantages including: a high fecundity capable of producing hundreds
of eggs with a single breeding; rapid embryonic development with most internal organs being fully
differentiated by 96 h post fertilization (hpf); as well as a nearly transparent outer chorion allowing for
development to be easily monitored using a light microscope [7]. As such, this model system is finding
utility in fields ranging from genetics to toxicology/pharmacology to biotechnology [9,10]; in our
prior studies [6–8], the zebrafish embryo assay has been specifically applied to identification
(i.e., screening), purification (i.e., bioassay-guided fractionation) and characterization of developmental
toxins from cyanobacteria.
As part of this on-going research, we previously evaluated [8] the cyanotoxin, cylindrospermopsin
(CYN), as well as extracts from unialgal cultures of several CYN producing and non-producing strains
of the widespread toxigenic cyanobacterial species, Cylindrospermopsis raciborskii and Aphanizomenon
ovalisporum. Although CYN was found to be toxic, apparent impermeability of the embryonic chorion
and/or cellular membranes, with respect to the water-soluble toxin, necessitated microinjection of the
pure compound in order for toxicity to be observed. In fact, a similar apparent impermeability—and
requirement for microinjection—was, likewise, observed for the equally water-soluble microcystins [11].
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Moreover, toxicity of microinjected CYN was generally only associated with a dose-dependent
increase in mortality of embryos, but no clear or reproducible developmental dysfunction [8]. In
contrast, however, concurrent evaluation of crude, non-polar (i.e., chloroform) extracts from strains of
both C. raciborskii and A. ovalisporum identified developmental toxicity, clearly unrelated to the
presence of CYN, and specifically associated with apparent lipophilic metabolites from extracts of all
of the isolates evaluated [8].
Toward understanding the possible contribution of these apparent lipophilic metabolites to the
toxigenicity of these cyanobacterial species, the present study used the zebrafish embryo bioassay to
guide purification for subsequent chemical and toxicological characterization of the previously
identified [8] developmental toxin(s) from one of these isolates. Specifically, this study focused on a
strain of A. ovalisporum previously isolated from Lake Kinneret, Israel, following a reported 1994
toxigenic bloom [12]. Aphanizomenon, as a genus, and particularly the species, A. flos-aquae, is a
recognized producer of CYN, as well as the neurotoxic saxitoxin and anatoxin-a. Although A. ovalisporum
is not known to produce either saxitoxin or anatoxin-a, studies of the Lake Kinneret isolate [12,13]
identified both CYN and its 7-epimer (i.e., 7-epi-CYN). Interestingly, and relevant to the present study,
during the isolation of the latter CYN congener, a series of isotactic polymethoxylated-1-alkenes (4–6;
Figure 1) were concurrently identified, purified and chemically characterized.
Indeed, in the present study, bioassay-guided fractionation, as described below, led to the isolation,
and chemical characterization of these previously identified polymethoxy-1-alkenes (PMAs), i.e., 4–6,
as well as three additional members (1–3) of the apparent homologous series (Figure 1), as lipophilic
developmental toxins from the Lake Kinneret strain of A. ovalisporum. Although three of the six
PMAs reported here have been isolated previously from this strain [13]—as well as at least two other
genera (i.e., Scytonema, Tolypothrix) of the cyanobacterial order Nostocales [14–16]—in studies
spanning more than three decades, they have not previously been associated with toxicity. In addition
to their isolation, and chemical characterization, we report here on their developmental toxicity in the
zebrafish embryo model, and specifically, the apparent synergistic activity of congeners in the series.
Figure 1. Structure of polymethoxy Alkenes (1–6) Isolated in the Current and
Previous [13–16] Studies.

2. Results and Discussion
2.1. Purification of PMAs by Bioassay-Guided Fractionation
Biomass from unialgal cultures of A. ovalisporum was (twice) extracted in CHCl3, and pooled
extracts were confirmed to inhibit zebrafish embryo development as previously documented [8]. The
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pooled crude extracts were subsequently fractionated (see Experimental Section) by silica gel column
chromatography and reverse-phase HPLC, affording a bioactive fraction containing a total of six
components (1–6; Figure 2). LC-MS of the active fraction identified nominal masses of the
presumptive molecular ions (M + H+) for compounds 1–6 of m/z 505 (1), 563 (2), 621 (3), 679 (4), 737
(5) and 795 (6), in addition to apparent, i.e., M + 23, sodium adducts (M + Na+) of each. An
incremental mass difference of 58 amu, corresponding to -CH2CH(OCH3)- units, between each of the
six compounds, as well as collision induced fragmentations, corresponding to sequential losses of
32 amu (-OCH3 lost as CH3OH) for each compound, was consistent with a homologous series of
PMAs, as previously observed for the strain [13] as well as other cyanobacteria [14–16]. Each of the
six peaks was collected for subsequent chemical and toxicological characterization (as described below).
Figure 2. Chromatogram Showing PMAs (1–6) Isolated by HPLC. See Experimental
Section for details.

2.2. Structure Elucidation of the PMAs
Compound 3 was the most abundant of the purified compounds and was isolated as a white
amorphous solid. A molecular formula of C34H68O9 was suggested by high-resolution MS (HRMS;
m/z 621.4920 [M + H]+), and subsequently confirmed by 1H and 13C-NMR studies (see below).
MS/MS of the presumptive molecular ion (m/z 621.5) in the triple quadrupole instrument identified
nine sequential losses of 32 amu consistent with nine methoxy groups (as MeOH) from the molecule.
1
H NMR (Table 1), likewise, revealed eight signals at δ 3.1641 (s, 3H), 3.2105 (s, 3H), 3.218 (s, 3H),
3.2432 (s, 3H), 3.2514 (s, 3H), 3.2708 (s, 3H), 3.2745 (s, 3H) and 3.2798 (s, 6H), consistent with nine
methoxy groups, with two of the methoxy groups being equivalent. Protons on the terminal alkene
were identified at δH 5.09 (H-1E), 5.13 (H-1Z) and 5.93 (H-2), and three methyl protons tentatively
assigned to C-25 (Figure 1) were observed at δH 0.91. Two sets of overlapping multiplets at δ 3.37
(m, 2H) and 3.65 (m, 7H) (Table 1) were assigned as oxymethine hydrogens geminal to the methoxy
groups, as confirmed by subsequent HMBC experiments (see below). Likewise, overlapping multiplets
were observed at δ 2.04 (m, 8H), 1.80 (m, 6H), 1.67 (m, 2H), 1.56 (m, 2H), 1.43 (m, 2H) and 1.30
(m, 4H), which integrated to a total of 24 protons. Based on distinct chemical shifts, and the
assumption that 3 was a PMA, 16 of these were tentatively assigned to the protons vicinal to methoxy
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groups (δ 2.04, 1.80 and 1.67), and the remaining eight protons (δ 1.56, 1.43 and 1.30) were assigned
to methylenes at C-21 to C-24 positions (Figure 1). Two additional methylene protons (δ 2.30) were
identified and assigned to the C-3 position (Figure 1), specifically based on COSY correlation
(see below) to the terminal alkene protons. Tentative proton assignments, and the proposed molecular
formula, were confirmed by 13C-NMR and DEPT, as well as subsequent HMQC and HMBC
experiments, as described below.
Table 1. 1H (C6D6, 400.13 MHz) and 13C (C6D6, 100.61 MHz) NMR Data for
4,6,8,10,12,14,16,18,20-nonamethoxy-1-pentacosene (3).
C#
1

δC
117.01

2
3
4
5, 7, 9…19
6, 8, 10…18
20
21
22
23
24
25
26–34

135.26
38.66
77.61
38.35–38.97
75.92–76.11
78.13
33.96
25.09
32.51
23.08
14.27
55.93–56.16

δH (mult, J in Hz; #H)
5.13 (dd, 17, 2; 1H)
5.09 (dd, 10, 2; 1H)
5.93 (ddt, 17, 10, 7; 1H)
2.30 (m; 2H)
3.37 (m; 1H)
1.67–2.04 (m; 16H)
3.65 (m; 7H)
3.37 (m; 1H)
1.56 (m; 2H)
1.43 (m; 2H)
1.30 (m; 2H)
1.30 (m; 2H)
0.91 (t, 7.1; 3H)
See text

COSY
H-2
H-2
H-1, H2-3
H-2, H-4
H-3, H2-5
See text
See text
H2-21, H2-19
H2-20, H2-22
H2-21, H2-23
H2-22, H2-24
H2-23, H2-25
H2-24

COSY experiments, in conjunction with HMQC and HMBC, revealed the apparent linear structure
of 3. Protons of the single methyl group (H3-25, δ 0.91) were found to correlate by COSY to two pairs
of hydrogens (δ 1.30) that were subsequently revealed, by HMQC correlations, to be bonded to two
methylene carbons. HMBC correlation of both methylene carbons to protons of the methyl group
further enabled assignment of C-25, -24 and -23 (as shown in Figure 1). COSY correlation of C-23/24
protons to a single pair of methylene protons (assigned as C-22), and subsequent correlation to a single
adjacent pair of methylene protons (assigned as C-21)—as well as COSY correlation of C-21
hydrogens to a pair of oxymethine protons (δ 3.37)—enabled assignments of hydrogens on C-25
through C-20 as shown in Figure 1. Similarly, at the alkene terminal (Figure 1), COSY correlation was
observed between alkene hydrogens and a single pair of methylene protons that was consequently
assigned to C-3. Although methylene protons on both C-21 and C-3 correlated to the same two
overlapping oxymethine proton signals (assigned C-20 and C-4, respectively), correlation of these
protons to C-22 methylene and C-1/2 terminal alkene protons, respectively, allowed these two pairs of
methylene hydrogens to be clearly distinguished.
Finally, a stretch of nine alternating methoxy-bearing carbons and the methylene carbons between
(C-4 to C-20; Figure 1) were identified based on correlations in COSY and HMBC. HMBC
correlations between proposed methoxy carbons (nine in total) and seven remaining oxymethine
protons, along with mass fragmentation (i.e., loss of 32 amu) consistent with –OCH3 functional groups,
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further confirmed their identity as methoxy-bearing carbons. Chemical shifts, in both 1H- and 13C-NMR
spectra, assigned to protons and carbons of the remaining methylenes and oxymethines, overlapped
considerably, and did not consequently allow resolution of these signals for direct correlations.
However, COSY and HMBC correlation of the total integrated signals for the methylene and
oxymethine protons (i.e., 16 and 9, respectively) and corresponding carbons (i.e., 8 and 9, respectively)
confirmed that methoxy-bearing carbons alternated with methylenes.
Accordingly, 3 was determined to be 4,6,8,10,12,14,16,18,20-nonamethoxy-1-pentacosene. As
such, this compound would represent a structural isomer of 4,6,8,10,12,14,16,18,22-nonamethoxy-1pentacosene previously isolated from the same strain by Banker et al. [13]. Although a new PMA
variant for this particular strain, 3 was, in fact, previously isolated by Mynderse and Moore [14] from
Tolypothrix conglutinata var. colorata—specifically as the similarly most abundant (~80%) of three
congeners isolated from this strain—as well as by Mori et al. [15] from Scytonema burmanicum. In
this case, as in other prior studies [13,15,16], methoxyl groups of the PMA were determined, based on
NMR studies, to be isotactic (i.e., on the same side of the alkene chain). Based on the nearly identical
1
H- and 13C-NMR observed here, 3 was proposed to be, likewise, isotactic.
Although quantities of each of the less abundant PMAs purified, including the more major (i.e., 2
and 4) and minor (i.e., 1, 5 and 6; see Figure 2) congeners, did not generally allow for 13C-NMR and
related NMR analysis (i.e., HMQC, HMBC), structures were assigned based on comparison to the
1
H-NMR and associated assignments based on COSY of 3 (as described above), as well as MS/MS
(i.e., losses of 32 amu corresponding each methoxy group). Furthermore, comparison of this data
(i.e., 1H-NMR, COSY, MS) to that previously published and available for characterization of PMAs,
and specifically, studies by Mynderse and Moore [14] and Mori et al. [15,16], were used to support
these structural assignments. A clear correlation (e.g., nearly identical 1H-NMR chemical shifts,
identical molecular ions and subsequent fragmentation patterns) between spectroscopic data obtained
for 2 and 4–6 in the present study, as well as those previously reported [13–16], support our structural
determinations for these less abundant variants. On the other hand, although 1 has not been previously
identified from any other source, consistency in the NMR and MS data for this congener, compared to
the other purified in the present study, strongly support the proposed structure of this variant. Similar
to 3, the stereochemistry—and specifically the assignment as isotactic methoxy groups—was,
likewise, concluded based on the similarities observed in the NMR data for these congeners and those
previously characterized [13,15,16]. Accordingly, 1 and 2 were identified as isotactic 4,6,8,10,12,
14,16-heptamethoxy-1-uncosene and 4,6,8,10,12,14,16,18-octamethoxy-1-tricosene, respectively. The
former variant (1) has not been previously isolated (to the authors’ knowledge) from cyanobacteria,
however, the latter (2) was previously isolated from T. conglutinata [14]. On the other hand, 4–6 were
identified as 4,6,8,10,12,14,16,18,20,22-decamethoxy-1-heptacosene, 4,6,8,10,12,14,16,18,20,22,24undecamethoxy-1-nonacosene and 4,6,8,10,12,14,16,18,20,22,24,26-dodecamethoxy-1-hentriacontene,
respectively, and each has been previously isolated from the Lake Kinneret isolate of A. ovalisporum [13]
and other cyanobacteria [15,16]. Additional members of the apparent homologous series, including
penta- and hexa-methoxylated variants, although not seen here, have been previously isolated from
species of Scytonema [15,16].
Interestingly, the linear polymethoxylated structure of the PMAs suggests a possible biosynthetic
origin based on the polyketide synthase (PKS) pathway found conspicuously throughout the secondary
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metabolism of fungi, bacteria and microalgae [17]. Indeed, this biosynthetic route—and specifically
the sequential condensation of acetate—for the PMAs has been previously suggested by other authors.
Banker et al. [13], for example, proposed such a biosynthetic origin based on both consideration of
structure, and the observation that PMAs were not found among A. ovalisporum cultures that lost
their ability to produce the PKS-derived CYN. Similarly, both Mynderse and Moore [14] and
Mori et al. [15,16] identified PMAs from strains of Tolypothrix and Scytonema, respectively, known to
produce the polyketide, tolytoxin. Given the abundance of PKS-derived secondary metabolites among
cyanobacteria and other microalgae, this biosynthetic origin may further support a widespread
distribution of the PMAs.
2.3. Toxicological Studies of PMAs
Although previously isolated from A. ovalisporum [13], and several other cyanobacterial
species [14–16], PMAs have not been previously associated with toxicity or other bioactivity. Indeed,
Mynderse and Moore [14] first isolated the isotactic PMAs, including 2, 3 and 4, as components of
―non-toxic mixture‖ while looking for the cytotoxic polyketide, tolytoxin A. As such, the present study
is the first report of the biological activity of the PMAs. It should, however, be noted that a parallel
series of polymethoxydienes isolated from the marine sponge, Myriastra clavosa, were found to be
moderately cytotoxic to a human colon cancer cell-line, and suggested in fact, based on chemical
similarity, to be derived (via diet and metabolic transformation) from cyanobacteria [18].
In the current study, five of the six PMAs (1–5) were obtained in sufficient (i.e., accurately
weighable) quantities, and subsequently evaluated for developmental toxicity in the zebrafish embryo
model. Zebrafish embryos, exposed (five embryos per concentration) to a representative concentration
range (10, 25, 50 and 100 µg/mL) of 1–5, were observed up to five days post-fertilization (dpf) for
mortality and apparent developmental dysfunction. It should be noted that solubility, and consequently
the absolute dissolved concentration, of PMAs in aqueous assay medium remains uncertain; however,
the assumption of relatively low water-solubility of these lipophilic compounds would suggest that
prepared exposure concentrations may, in fact, overestimate actual dissolved exposure concentrations.
Notably, toxicity of PMAs in the zebrafish embryo assay seemed to correlate with chain length
and/or associated degree of methoxylation of the variants. With regards to embryo mortality (Table 2),
no effect was observed at the lowest exposure concentrations (10 and 25 µg mL−1) for any of the
variants tested. In a typical experiment, however, 100% mortality at 5 dpf was observed for embryos
exposed to both 50 and 100 µg mL−1 of the three smallest congeners (1–3), whereas relatively little
(i.e., 20%–40%) or no mortality for the same doses were observed for embryos exposed to the two
increasingly larger congeners (i.e., 4 and 5, respectively) tested. For comparison, mortality in untreated
controls was very low (i.e., approximately 1.7%, n = 60 embryos). Similarly, there was an apparently
parallel, congener-dependent effect on hatching rates (Table 2). Again, little or no effect on hatching
(i.e., 80%–100% hatching rate at 4 dpf) was observed for lowest exposure concentrations (10 and
25 µg mL−1) of any of the PMAs tested relative to the untreated controls (98% hatching, n = 60 eggs).
However, the hatching of embryos was inhibited by PMAs in a dose- and congener-dependent manner
at the two highest exposure concentrations (50 and 100 µg mL−1). Specifically, hatching (4 dpf) was
completely inhibited in embryos exposed to 100 µg mL−1 of congeners 1–3, but only partially inhibited

Mar. Drugs 2012, 10

2329

for embryos exposed to 4, and not appreciably affected in embryos exposed to the largest variant (5).
Supporting a dose and congener dependent effect, at 50 µg mL−1 hatching was completely inhibited by
only the two smallest congeners (1 and 2), and decreasingly affected by the larger 3–5. These
observations were further supported by a preliminary evaluation of 3–5, which were initially purified
in sufficient quantities to test. This preliminary exposure study showed a similar pattern to that
reported in Table 2 for these congeners, with 3 causing 100% mortality as well as gross development
defects at the highest concentrations tested (50 and 100 µg mL−1), while 4 caused only low mortality
(20%) at the highest concentration (100 µg mL−1) and none at lower concentrations, and 5 did not
cause mortality at any exposure level at 5 dpf. Although little or no mortality was observed for
embryos exposed to 4 at these highest concentrations, all surviving embryos were characterized by
developmental dysfunction and deformity (as discussed further below); in contrast, no distinguishable
effects on development were observed for embryos exposed to any concentration of 5. Thus, while the
limited availability of purified material precluded conducting a full-scale quantitative toxicological
characterization of the PMAs, the consistency of the trends observed strongly supports a dose and
congener related toxicity effect on these embryos.
Table 2. Mortality and Hatching Rates for Zebrafish Embryos Exposed to PMAs (1–5)
from A. ovalisporum (Lake Kinneret, Israel). Mortality was recorded at five days
post-fertilization (dpf) for five embryos per concentration. Hatching rates were recorded
at 4 dpf.
% Mortality (5 dpf) b
a

PMA
Conc.:
1
2
3
4
5

10
20%
0%
0%
0%
0%

25
0%
0%
0%
0%
0%

50
100%
100%
100%
40%
0%

Hatching Rate (4 dpf) b
100
100%
100%
100%
20%
0%

10
100%
100%
100%
100%
100%

Concentration of PMAs tested at 10, 25, 50 and 100 µg mL−1;
approximately 1.7%, while hatching rate was 98% (n = 60 embryos).
a

b

25
100%
80%
80%
100%
100%

50
0%
0%
40%
60%
80%

100
0%
0%
0%
60%
80%

In untreated controls, mortality was

In addition to the effects on mortality and hatching rate, there was also an apparent correlation
between both exposure dose and structural variation of the PMAs (i.e., degree of methoxylation, chain
length) and observed morphological developmental effects (Figure 3). At the highest concentration
tested (100 µg mL−1), embryos exposed to the smallest congener (1) exhibited several indications of
severely impaired development (Figure 3E), including near lack of pigmentation, impaired
organogenesis (e.g., reduced eye formation), deformity of the yolk sac and other gross abnormalities.
Although developmental effects were less profound for congeners 2 and 3 at the same exposure
concentration (100 µg mL−1), embryos exposed to both of these larger variants were also characterized
(Figure 3F,G, respectively) by similar defects as well as the formation of edemas (along with reduced
hatching rates; see above). Developmental dysfunction was uniformly observed (i.e., 100% of
embryos), although the severity of this dysfunction varied, and in each case, was followed by embryo
mortality by 5–6 dpf. In contrast, embryos exposed to the highest dosage of congener 4 showed
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relatively limited developmental effects (e.g., slightly curved body axes; Figure 3H) and those exposed
to 5 were indistinguishable (data not shown) from untreated controls (Figure 3I). Development was
also inhibited and abnormal in all embryos exposed to a lower concentration (50 µg mL−1) of 1–3, but
there was no clear correlation of prevalence or severity of defects with congener size. (Figure 3A–C).
However, similar to the effects observed at the higher concentrations, there were clearly minimal
effects of congener 4 (Figure 3D) and no detectable effects associated with 5. One particularly notable
effect observed was an apparent pooling of blood between the anterior surface of the yolk and the heart
in embryos exposed to 1–3 (indicated by arrows in Figure 3); this was most obvious in embryos
exposed to the lower concentration (50 µg mL−1) of all three of these congeners and the higher
concentration (100 µg mL−1) of the largest of these variants (3). This effect was not observed in the
more severely deformed embryos exposed to the highest concentration of 1 and 2, where it was likely
obscured by the numerous severe developmental defects present in these fish. As for the assessment of
mortality and hatching rate (see above; Table 2), data from a single experiment are presented, due to
limitations of purified PMAs. However, additional studies with a subset of these congeners, including
both evaluation of initially purified amounts of 3–5 (as discussed above), and the subsequent
evaluation of 3 and 4 with respect to apparent interactive effects (Figure 4; discussed below), likewise
generally confirm the observed congener-dependent trend of delayed and/or dysfunctional development.
Figure 3. Developmental Toxicity of PMAs (1–4) Isolated from A. ovalisporum (Lake
Kinneret, Israel). Photomicrographs of embryos at 4 dpf. Shown are embryos exposed to
1–4 at 50 µg mL−1 (A–D, respectively) and 100 µg mL−1 (E–H, respectively). Untreated
control embryo at 4 dpf (I) shown for comparison. Arrows indicate areas where blood is
pooled adjacent to the heart. Images in A–C and E–G, are not to scale with D, H and I.

Based on the qualitatively more pronounced developmental toxicity observed during bioassay-guided
fractionation compared to that of individual congeners, we evaluated pair-wise combinations of 3 and
4—as two of the most abundant variants (i.e., purified in the largest quantity) with the latter showing
only relatively limited toxicity—in order to assess possible synergistic and/or additive effects of the
PMAs. Interestingly, a clear interactive effect of the congeners, in terms of embryos toxicity, was
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observed for embryos exposed to a combination of two variants when compared to either 3 or 4,
individually. Embryos exposed to 50 and 100 µg mL−1 of each compound were characterized by the
typically moderate developmental dysfunction observed for these variants (Figure 3 and 4A–C).
However, when exposed to equivalent total concentrations comprised of equal amounts congeners 3
and 4 (i.e., 25 µg mL−1 and 50 µg mL−1, respectively, of 3 and 4), there was a clearly more pronounced
inhibition of development (Figure 4D,E). All embryos exposed to both combined concentrations were
characterized by a severe inhibition of organogenesis and overall differentiation and development of
the embryo that was not observed for embryos exposed to any of the congeners individually at an
equivalent concentration. This observation is consistent with a synergistic effect of these variants and
may explain increased toxicity of PMA mixtures (when compared to individual variants). Synergistic
interactions of biologically active cyanobacterial metabolites have been previously reported. Recently,
for example, Leão et al. [19] documented similar synergistic effects with regards to algicidal activity
of the cyclic peptide congeners, portoamides A and B, isolated as apparent allelochemicals from a
freshwater strain of Oscillatoria. Likewise, a similarly synergistic effect of lobocyclamides A and B,
isolated from a marine cyanobacterial species, Lyngbya confervoides, was previously reported [20],
specifically in relation to antifungal activity of these lipopeptides.
Figure 4. Apparent Synergistic Interactions in the Developmental Toxicity of 3 and 4.
Shown are embryos exposed to 50 µg mL−1 of 3 (A), and 100 µg mL−1 of 3 (B) and 4 (C),
compared to an equivalent combined total concentration (i.e., 25 and 50 µg mL−1 of each)
of the two variants (D and E, respectively). Embryos shown at 4 dpf.
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The identification of toxicity associated with the PMAs, combined with the previous isolation of related
variants from other distantly related marine, freshwater and terrestrial cyanobacterial genera [14–16],
as well as the cyanobacterially derived polymethoxydienes found in marine sponges [18], suggest that
PMAs may represent a relatively widespread toxic metabolite from the blue-green algae. Moreover,
preliminary evaluation by LC-MS, and subsequent purification and identification (by MS and
1
H-NMR), confirmed the presence of 1–6 in the extracellular medium of the A. ovalisporum cultures
(data not shown), and suggests that these lipophilic metabolites may, to some degree, be released—either
actively by excretion, or passively via senescence of algal cells—into the surrounding aqueous
environment. Accordingly, it is proposed that the presence of these lipophilic metabolites may not
only contribute to previously observed toxicity associated with lipophilic fractions of toxigenic
cyanobacteria [8], but to the observed toxicity of the bloom-forming cyanobacteria more generally.
3. Experimental Section
3.1. Culturing of the Cyanobacteria
The isolate of A. ovalisporum, (designated APH 127-1) was grown, as previously described [7,8,21],
in 3-L flasks in BG11 medium under cool-white fluorescent light (intensity 30 µEm−2∙s−1) with
aeration. The cells/biomass were harvested after three to four weeks by centrifugation and freeze-dried.
3.2. Extraction and Isolation of Polymethoxy-1-alkenes
Isolation and purification of the polymethoxy-1-alkenes was carried out by a bioassay-guided
fractionation using the zebrafish embryo model. Freeze-dried biomass of A. ovalisporum was extracted
in chloroform in a 10:1 ratio overnight. The filtered extract was initially fractionated by flash
chromatography on a normal phase silica-gel glass column (Silica Gel 60Å, Commercial 40–63 μm)
with a stepwise gradient of ethyl acetate in hexane; a bioactive fraction (as identified with the zebrafish
embryo toxicity assay; see below) eluted with 100% ethyl acetate. This bioactive (i.e., 100% ethyl
acetate) fraction was further separated by reverse-phase HPLC (Phenomenex Luna 5 µm C18 100 Å
LC Column 30 × 4.6 mm; solvent gradient of 50:50 acetonitrile/water to 100% acetonitrile for 37 min)
with UV detection (i.e., 200 nm absorbance). The crude mixture of all six polymethoxy-1-alkenes
eluted with retention times between 21 and 24 min. This mixture of polymethoxy-1-alkenes was
confirmed to be toxic in the zebrafish embryo model (see below), and individual PMAs were purified
by HPLC-UV (isocratic 65:35 acetonitrile/water) with the compounds eluting in order of increasing
size (see Figure 2).
3.3. Zebrafish Embryo Bioassay
The zebrafish (Danio rerio) embryo was used as a model of developmental toxicity for both
bioassay-guided fractionation and subsequent toxicological characterization. The maintenance and
breeding of adult zebrafish, and the embryo toxicity bioassays, were carried out as previously
described by Berry et al. [7,8] and according to protocols approved by the FIU Institutional Animal
Care and Use Committee (IACUC). Toxicity was evaluated in solvent-resistant, polypropylene 24-well
plates (Evergreen Scientific, Los Angeles, CA) with five embryos per well in E3 medium [22].
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Extracts and fractions were typically evaluated at a high- (100 µL) and low- (10 µL) exposure
concentration; purified PMAs were evaluated at concentrations of two, five, 10, 25, 50 and 100 µg/mL
concentrations (in acetonitrile), and purified 3 and 4 were specifically evaluated in combination at
10, 25 and 50 µg/mL of each (20, 50 and 100 µg/mL total) to evaluate synergistic activity. Vehicle
(i.e., acetonitrile-only) and ―untreated‖ controls, respectively, were included in each assay; the solvent
was evaporated from assay plates, prior to adding medium and embryos, and accordingly there was no
observed effect of the solvent (relative to the untreated controls). The embryos were observed up to
5 days post fertilization (dpf) for bioactivity. In addition to percent hatching and mortality,
developmental toxicity was recorded by photomicrography using an Olympus SZX7 stereomicroscope
equipped with an Olympus DP72 digital camera.
3.4. Characterization of Polymethoxy-1-alkenes
Purified compounds were characterized by NMR and mass spectrometry. 1H- and 13C/DEPT-NMR,
as well as two-dimensional homonuclear (i.e., COSY) and heteronuclear (i.e., HMQC and HMBC)
analyses, were done on a Bruker AVANCE 400 MHz instrument. Mass spectrometry was performed
on a Thermo TSQ Quantum Access ESI/triple quadrupole instrument coupled to a Thermo Accela
UHPLC; high-resolution mass spectrometry data was done at the Scripps Florida Mass Spectrometry
and Proteomics laboratory (Jupiter, FL) on a Thermo LTQ ESI-Orbitrap.
4,6,8,10,12,14,16-heptamethoxy-1-uncosene (1): LCMS m/z 505 (C28H56O7, [M + H]+); 1H NMR
(400 MHz, benzene-d6) δ 0.91 (t, 3H, J = 7.1 Hz), 1.30 (m, 4H), 1.43 (m, 2H), 1.56 (m, 2H), 1.67 (m,
2H), 1.81 (m, 4H), 2.02 (m, 6H), 2.30 (m, 2H), 3.16 (s, 3H), 3.21 (s, 3H), 3.22 (s, 3H), 3.24 (s, 3H),
3.25 (s, 3H), 3.27 (s, 3H), 3.27 (s, 3H), 3.37 (m, 2H), 3.64 (m, 5H), 5.07 (dd, 1H, J = 10,2 Hz), 5.09
(dd, 1H, J = 17, 2 Hz), 5.90 (ddt, 1H, J = 17, 10, 7 Hz).
4,6,8,10,12,14,16,18-octamethoxy-1-tricosene (2): LCMS m/z 563 (C31H62O8, [M + H]+); 1H NMR
(400 MHz, benzene-d6) δ 0.91 (t, 3H, J = 7.1 Hz), 1.30 (m, 4H), 1.42 (m, 2H), 1.56 (m, 2H), 1.67 (m,
2H), 1.81 (m, 5H), 2.03 (m, 7H), 2.30 (m, 2H), 3.16 (s, 3H), 3.21 (s, 3H), 3.22 (s, 3H), 3.24 (s, 3H),
3.25 (s, 3H), 3.27 (s, 3H), 3.27 (s, 3H), 3.28 (s, 3H), 3.37 (m, 2H), 3.64 (m, 6H), 5.07 (dd, 1H,
J = 10, 2 Hz), 5.09 (dd, 1H, J = 17, 2 Hz), 5.90 (ddt, 1H, J = 17, 10, 7 Hz).
4,6,8,10,12,14,16,18,20-Nonamethoxy-1-pentacosene (3): LCMS m/z 621.4944 (C34H68O9, [M + H]+);
1
H NMR (400 MHz, benzene-d6) δ 0.91 (t, 3H, J = 7.1 Hz), 1.30 (m, 4H), 1.43 (m, 2H), 1.56 (m, 2H),
1.67 (m, 2H), 1.80 (m, 6H), 2.04 (m, 8H), 2.30 (m, 2H), 3.1641 (s, 3H), 3.2105 (s, 3H), 3.218 (s, 3H),
3.2432 (s, 3H), 3.2514 (s, 3H), 3.2708 (s, 3H), 3.2745 (s, 3H), and 3.2798 (s, 6H), 3.37 (m, 2H), 3.65
(m, 7H), 5.09 (dd, 1H, J = 10, 2 Hz), 5.13 (dd, 1H, J = 17, 2 Hz), 5.93 (ddt, 1H, J = 17, 10, 7 Hz);
13
C NMR (100 MHz, benzene-d6) δ 14.3, 23.1, 25.1, 32.5, 33.9, 38.0, 38.2, 38.3, 38.6, 38.6 (3C), 38.7
(4C), 55.9, 56.0, 56.0 (3C), 56.0 (2C), 56.1, 56.1, 75.6, 75.7 (2C), 75.7, 75.8, 77.6, 78.1, 117.0, 135.3.
4,6,8,10,12,14,16,18,20,22-Decamethoxy-1-heptacosene (4): LCMS m/z 679.5347 (C37H74O10,
[M + H]+); 1H NMR (400 MHz, benzene-d6) δ 0.91 (t, 3H, J = 7.1 Hz), 1.30 (m, 4H), 1.44 (m, 2H),
1.58 (m, 2H), 1.68 (m, 2H), 1.81 (m, 7H), 2.03 (m, 9H), 2.30 (m, 2H), 3.16 (s, 3H), 3.21 (s, 3H), 3.22
(s, 3H), 3.24 (s, 3H), 3.25 (s, 3H), 3.27 (s, 3H), 3.27 (s, 3H), 3.28 (s, 9H), 3.37 (m, 2H), 3.64 (m, 8H),
5.07 (dd, 1H, J = 10, 2 Hz), 5.10 (dd, 1H, J = 17, 2 Hz), 5.90 (ddt, 1H, J = 17, 10, 7 Hz).
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4,6,8,10,12,14,16,18,20,22,24-Undecamethoxy-1-nonacosene (5): LCMS m/z 737 (C40H80O11,
[M + H]+); 1H NMR (400 MHz, benzene-d6) δ 0.91 (t, 3H, J = 7.1 Hz), 1.30 (m, 4H), 1.44 (m, 2H),
1.57 (m, 2H), 1.68 (m, 2H), 1.81 (m, 8H), 2.03 (m, 10H), 2.30 (m, 2H), 3.16 (s, 3H), 3.21 (s, 3H), 3.22
(s, 3H), 3.24 (s, 3H), 3.25 (s, 3H), 3.27 (s, 6H), 3.27 (s, 3H), 3.28 (s, 9H), 3.37 (m, 2H), 3.64 (m, 9H),
5.07 (dd, 1H, J = 10, 2 Hz), 5.10 (dd, 1H, J = 17, 2 Hz), 5.90 (ddt, 1H, J = 17, 10, 7 Hz).
4,6,8,10,12,14,16,18,20,22,24,26-dodecamethoxy-1-hentriacontene (6): LCMS m/z 795 (C43H86O12,
[M + H]+); 1H NMR (400 MHz, benzene-d6) δ 0.91 (t, 3H, J = 7.1 Hz), 1.30 (m, 4H), 1.44 (m, 2H),
1.57 (m, 2H), 1.68 (m, 2H), 1.81 (m, 9H), 2.03 (m, 11H), 2.30 (m, 2H), 3.16 (s, 3H), 3.21 (s, 3H), 3.22
(s, 3H), 3.24 (s, 3H), 3.25 (s, 3H), 3.27 (s, 6H), 3.27 (s, 3H), 3.28 (s, 12H), 3.37 (m, 2H), 3.64 (m,
10H), 5.07 (dd, 1H, J = 10, 2 Hz), 5.10 (dd, 1H, J = 17, 2 Hz), 5.90 (ddt, 1H, J = 17, 10, 7 Hz).
4. Conclusions
In the present study, we used the zebrafish embryo model to identify, isolate (via bioassay-guided
fractionation) and characterize a homologous series (Figures 1 and 2) of isotactic PMAs, including one
novel variant, as toxic components of the lipophilic fraction of the Lake Kinneret isolate of
A. ovalisporum. Although, toxicological evaluation of these compounds was somewhat limited by
availability of purified amounts of the toxins—particularly given the relatively low solubility/activity
and high exposure concentrations required for the individual congeners—our initial studies suggest
both a dose-dependent toxicity relationship (Figure 3) and a relationship between toxicity in the
zebrafish embryo model and structural variations (i.e., chain length, degree of methoxylation) of the
congeners. Moreover, evaluation of the interactive effects indicates a possible synergism between
variants with enhanced developmental toxicity (Figure 4) observed for pair-wise combinations of the
PMAs (e.g., 3 and 4). Toxicological investigation (and required purification of additional material) of
the PMAs in the zebrafish model is currently underway and will be presented elsewhere.
To our knowledge, this is the first report of the PMAs as toxic or otherwise bioactive metabolites.
It is, accordingly, suggested that these metabolites may not only explain previously observed
developmental toxicity [8] of lipophilic fractions from A. ovalisporum, but that these previously
unrecognized (as toxic) components may contribute to the overall toxicity of this CYN-producing
bloom species, and to the cyanobacteria perhaps more generally. Indeed, the prior isolation of these
compounds (albeit as non-toxic metabolites) from other cyanobacterial species [13–16,18] may
suggest that these toxic metabolites are relatively widespread, particularly within the cyanobacteria. As
such, these findings suggest a need to further investigate these possibly widespread toxic metabolites
of the cyanobacteria. To this end, studies to isolate and chemically and toxicologically characterize
PMAs from additional cyanobacterial species are currently on-going.
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